Company

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform
AbbVieAuto-immune

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Nxera Pharma (TYO: 4565) announced that its subsidiary, Nxera Pharma UK Ltd, has entered into an exclusive global license agreement with AbbVie (NYSE: ABBV), granting AbbVie exclusive rights to develop…

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Hybio Pharmaceutical's HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market

Hybio Pharmaceutical’s HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
FDA Approves AstraZeneca's Datopotamab deruxtecan for EGFR-Mutated NSCLC
ADC / XDCAstraZeneca

FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC

TransThera Sciences' Tinengotinib Gains FDA Fast Track for mCRPC Treatment
CancerHKG: 2617

TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development
AIDoveTree

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development

Merck's Prevymis Approved in China for Pediatric CMV Prevention
Merck Sharp & DohmeMSD

Merck’s Prevymis Approved in China for Pediatric CMV Prevention

Show More